Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an update.
Neuren Pharmaceuticals Limited announced a change in the director’s interest, with Director Joseph Basile acquiring 14,500 ordinary shares through an on-market trade. This acquisition increases his total holdings to 35,906 shares, reflecting a significant personal investment in the company. Such a move could indicate confidence in the company’s future prospects and may positively influence stakeholder perceptions.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a company operating in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company is known for its work in creating innovative treatments aimed at improving the quality of life for individuals with neurological conditions.
YTD Price Performance: -11.98%
Average Trading Volume: 852
Technical Sentiment Signal: Buy
Current Market Cap: $904.4M
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.